Christof Vulsteke

12PUBLICATIONS
110CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 01, 2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

|May 14, 2025
Severe hypocalcemia due to osteoblastic bone metastases in a patient with hypoparathyroidism: a case report.

Ode Devos, Christof Vulsteke, Emmanuelle Versele

|Nov 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.

Christian Marth, Richard G Moore, Mariusz Bidziński

|Oct 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles

|Oct 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Brian M Slomovitz, David Cibula, Weiguo Lv

|Jul 27, 2024
Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors.

Danielle Delombaerde, Christof Vulsteke, Nico Van de Veire

Pageof 2

Frequent Collaborators

3 joint publications

Hans Prenen

2 joint publications

Manuel Magallanes-Maciel

2 joint publications

Danielle Delombaerde

1 joint publications

Vicky Makker